非小细胞肺癌脑转移的靶向药物治疗进展

摘要
图/表
参考文献(25)
相关文章 (15)

全文: PDF (627 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺癌最常见的远处转移部位为脑部，目前非小细胞肺癌（NSCLC）脑转移治疗手段有化疗、放疗、分子靶向治疗和免疫治疗。对存在特定驱动基因突变的脑转移患者，分子靶向药已取得显著疗效，其中靶向药物联合立体定向放射治疗可显著提高患者的颅内缓解率、无进展生存期及总生存时间。目前一线靶向药物获得性耐药和治疗后进展是临床面临的主要问题。本文对NSCLC脑转移分子靶向治疗及其现况和进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李文格戈伟

关键词 ：肺癌, 脑转移, 分子靶向治疗, 联合治疗

Abstract：The most common distant metastasis of lung cancer is in the brain. Currently, the treatment methods for brain metastasis of non-small cell lung cancer (NSCLC) include chemotherapy, radiotherapy, molecular targeted therapy and immunotherapy. For patients with brain metastasis with specific driver gene mutations, molecular targeted drugs have achieved significant effects, among which targeted drugs combined with stereotactic radiotherapy can significantly improve the intracranial remission rate, progression-free survival and total survival time of patients. At present, the acquired drug resistance and post-treatment progress of first-line targeted drugs are the main problems in clinical practice. In this review, molecular targeting therapy for brain metastasis of NSCLC and its current status and progress are reviewed.

Key words： Lung cancer Brain metastasis Molecular targeted therapy Combination therapy

基金资助:国家重点研发计划项目（2016YFC1303800）。

通讯作者: 戈伟（1960-），男，博士，主任医师，硕士生导师；研究方向：肿瘤靶向治疗、肿瘤微循环与放射性治疗、肿瘤综合诊治。

引用本文:

李文格戈伟. 非小细胞肺癌脑转移的靶向药物治疗进展[J]. 中国医药导报, 2019, 16(34): 42-45,53.
LI Wen′ge GE Wei. Advances in targeted drug therapy for brain metastasis of non-small cell lung cancer. 中国医药导报, 2019, 16(34): 42-45,53.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I34/42

[1] Miller KD，Nogueira L，Mariotto AB，et al. Cancer treatment and survivorship statistics，2019 [J]. CA Cancer J Clin，2019，69（5）：363-385.
[2] Pedrosa RMSM，Mustafa DAM，Aerts JGJV，et al. Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis [J]. Front Oncol，2018，8：159.
[3] Xu J，Du Y，Liu XJ，et al. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy [J]. Pharmacol Res，2017，126：66-76.
[4] Shi Y，Au JS，Thongprasert S，et al. A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology（PIONEER） [J]. J Thorac Oncol，2014，9（2）：154-162.
[5] 王恩华，朱明华，步宏，等.非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J].中华病理学杂志，2016（2）：73-77.
[6] Phan TT，Tran BT，Nguyen ST，et al. EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer [J]. Clin Transl Med，2019，8（1）：4.
[7] Arbour KC，Kris MG，Riely GJ，et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases [J]. Cancer，2018，124（1）：105-109.
[8] Tan J，Li M，Zhong W，et al. Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC：A direct comparative analysis of icotinib，gefitinib，and erlotinib in a nude mouse model [J]. Oncotarget，2017，8（58）：98771-98781.
[9] Wei YF，Lim CK，Tsai MS，et al. Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases [J]. Clin Lung Cancer，2019，20（3）：e274-e283.
[10] Schuler M，Wu YL，Hirsh V，et al. First Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases [J]. J Thorac Oncol，2016，11（3）：380-390.
[11] Goss G，Tsai CM，Shepherd FA，et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer（AURA2）：a multicentre，open-label，single-arm，phase 2 study [J]. Lancet Oncol，2016，17（12）：1643-1652.
[12] Soria JC，Ohe Y，Vansteenkiste J，et al. Osimertinib in Untreated EGFR-Mutated Advanced Non - Small - Cell Lung Cancer [J]. N Engl J Med，2018，378（2）：113-125.
[13] Koba T，Kijima T，Takimoto T，et al. Rapid intracranial response to osimertinib，without radiotherapy，in nonsmall cell lung cancer patients harboring the EGFR T790M mutation：Two Case Reports [J]. Medicine (Baltimore)，2017，96（6）：e6087.
[14] He ZY，Li MF，Lin JH，et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases：a retrospective cohort study [J]. Cancer Manag Res，2019，11：2129-2138.
[15] Barlesi F，Mazieres J，Merlio JP，et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer：results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup（IFCT）[J]. Lancet，2016，387（10026）：1415-1426.
[16] Dagogo-Jack I，Shaw AT. Crizotinib resistance：implications for therapeutic strategies [J]. Ann Oncol，2016， 27 Suppl 3:iii42-iii50.
[17] Tomasini P，Egea J，Souquet-Bressand M，et al. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer：clinical trial evidence and experience with a focus on brain metastases [J]. Ther Adv Respir Dis，2019，13：1753466619831906.
[18] Hida T，Nokihara H，Kondo M，et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer （J-ALEX）：an open-label，randomised phase 3 trial [J]. Lancet，2017，390（10089）：29-39.
[19] Nishio M，Nakagawa K，Mitsudomi T，et al. Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer [J]. Lung Cancer，2018，121：37-40.
[20] Peters S，Camidge DR，Shaw AT，et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer [J]. N Engl J Med，2017，377（9）：829-838.
[21] Mcleer-Florin A，Duruisseaux M，Pinsolle J，et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer [J]. Lung cancer，2018，116：15-24.
[22] Frezzetti D，Gallo M，Maiello MR，et al. VEGF as a potential target in lung cancer [J]. Expert Opin Ther Targets，2017，21（10）：959-966.
[23] Besse B，Le Moulec S，Mazières J，et al. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic，Untreated Brain Metastases （BRAIN）：A Nonrandomized，Phase II Study [J]. Clin Cancer Res，2015，21（8）：1896-1903.
[24] Lévy C，Allouache D，Lacroix J，et al. REBECA：a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours [J]. Ann Oncol，2015，26（11）：2359.
[25] Brastianos PK，Carter SL，Santagata S，et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets [J]. Cancer Discov，2015，5（11）：1164-1177.